Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line
by Markus Aldén 1,Francisko Olofsson Falla 1,Daowei Yang 1,Mohammad Barghouth 1,Cheng Luan 1,Magnus Rasmussen 2 andYang De Marinis 1,* Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden2Infection Medicine, Department of Clinical Sciences, Lund University, 22362 Lund, Sweden*Author to whom correspondence should be addressed.Academic Editor: Stephen MalnickCurr. Issues Mol. Biol.2022, 44(3), 1115-1126; https://doi.org/10.3390/cimb44030073Received: 18 January 2022 / Revised: 19 February 2022 / Accepted: 23 February 2022 / Published: 25 February 2022 Abstract Preclinical studies of COVID-19 mRNA vaccine BNT162b2, developed by Pfizer and BioNTech, showed reversible hepatic effects in animals that received the BNT162b2 injection. Furthermore, a…






